Arcutis biotherapeutics stock.
Shares of Arcutis Biotherapeutics ( ARQT -3.16%) climbed 21.2% for the week after rising as high as 23.8%, according to data provided by S&P Global Market Intelligence. The medical dermatology ...
Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions.Mar 7, 2023 · As of March 07, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $13.69. Arcutis Biotherapeutics Inc is down 5.85% from its previous closing price of $14.54. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $14.43 and $15.47. Currently, there are 61.04 million shares of Arcutis ... Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) | 16,482 followers on LinkedIn. Bioscience, applied to the skin. | Arcutis (Nasdaq: ARQT) was founded in 2016 to address significant unmet needs in ...Arcutis Biotherapeutics Stock Price, News & Analysis (NASDAQ:ARQT) $1.99 +0.15 (+8.15%) (As of 12/1/2023 ET) Compare Today's Range $1.76 $2.00 50-Day …
May 9, 2023 · ARCUTIS BIOTHERAPEUTICS, INC. Condensed Balance Sheets (In thousands) March 31, December 31, 2023 2022 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 81,405 $ 53,641 Restricted cash 925 1,234 Trade receivable, net 12,769 8,458 Marketable securities 251,000 355,948 Inventories 8,551
WESTLAKE VILLAGE, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) (“Arcutis”), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of common …Nov 3, 2023 · ARQT stock had a significant performance on November 3, 2023. According to data from CNN Money, eight analysts have offered 12-month price forecasts for Arcutis Biotherapeutics Inc, with a median target of $33.00. The high estimate for the stock price is $50.00, while the low estimate is $4.00.
Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, ACADIA Pharmaceuticals, and Alkermes. According to TipRanks , Ear has an average return of 13.4% and a 32.14% ...These 8 analysts have an average price target of $25.62 versus the current price of Arcutis Biotherapeutics at $2.49, implying upside. Below is a summary of how these 8 analysts rated Arcutis ...Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated ...Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with ...About Arcutis Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient …
Arcutis Biotherapeutics (ARQT) In a report released today, Serge Belanger from Needham maintained a Buy rating on Arcutis Biotherapeutics, with a price target of $24.00 . The company’s shares ...
See the company profile for Arcutis Biotherapeutics, Inc. (ARQT) including business summary, industry/sector information, number of employees, business summary, corporate governance, key ...
About Arcutis Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis …Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.Arcutis Biotherapeutics Inc is down 6.97% from its previous closing price of $7.82. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $7.82 and $8.26. Currently, there are 61.43 million shares of Arcutis Biotherapeutics Inc stock available for purchase. Unfortunately, Arcutis Biotherapeutics Inc’s P/E ratio ...WESTLAKE VILLAGE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (“Arcutis”) (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $20.00 per share ...The replay of the webcast will be available on the Arcutis website following the call. About Arcutis . Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions.
Arcutis Biotherapeutics, Inc. Common Stock (ARQT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Do the numbers hold clues to what lies ahead for the stock? Arcutis Biotherapeutics, Inc. (ARQT) delivered earnings and revenue surprises of 4.92% and 6.64%, respectively, for the quarter ended ...Chris Shibutani, an analyst from Goldman Sachs, maintained the Hold rating on Arcutis Biotherapeutics (ARQT – Research Report). The associated price target is $6.00. Chris Shibutani has given ...Insider Monkey Transcripts. Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) Q4 2022 Earnings Call Transcript February 28, 2023. Operator: Ladies and gentlemen, thank you for standing by. And welcome ...The latest price target for Arcutis Biotherapeutics ( NASDAQ: ARQT) was reported by Morgan Stanley on Monday, November 13, 2023. The analyst firm set a price target for 10.00 expecting ARQT to ...
Arcutis Biotherapeutics Stock Performance. ARQT opened at $2.34 on Monday. Arcutis Biotherapeutics has a 52-week low of $2.13 and a 52-week high of $20.11. The firm has a market capitalization of ...
Stock Quote & Chart. Change. Volume. Today's Open. Previous Close. Today's High. Today's Low. 52 Week High. 52 Week Low.Apr 11, 2023 · As of April 11, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $12.89. Arcutis Biotherapeutics Inc is up 4.2% from its previous closing price of $12.37. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $11.83 and $12.47. Currently, there are 61.04 million shares of Arcutis Biotherapeutics ... The stock options have a ten-year term and an exercise price of $7.65 per share, equal to the per share closing price of Arcutis’ common stock as reported by Nasdaq on June 1, 2023. Arcutis is ...Arcutis Biotherapeutics, Inc. is a medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Apr 6, 2023 · Arcutis Biotherapeutics Inc’s Stock Price as of Market Close. As of April 06, 2023, 4:00 PM CST, Arcutis Biotherapeutics Inc’s stock price was $12.03. Arcutis Biotherapeutics Inc is up 8.48% from its previous closing price of $11.09. During the last market session, Arcutis Biotherapeutics Inc’s stock traded between $10.67 and $11.23. ISIN. US03969K1088. Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar ...May 9, 2023 · ARCUTIS BIOTHERAPEUTICS, INC. Condensed Balance Sheets (In thousands) March 31, December 31, 2023 2022 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 81,405 $ 53,641 Restricted cash 925 1,234 Trade receivable, net 12,769 8,458 Marketable securities 251,000 355,948 Inventories 8,551
At Arcutis, we fiercely value people—our patients, healthcare providers, team members, and our community at large. We aspire to be an upstanding global figure, with strong ethical standards embedded in our culture, and guiding our actions. We are a Great Place to Work ® -Certified company, a 2022 Fortune Best Workplaces in Biopharma™, and ...
Arcutis Biotherapeutics will offer 4 million shares of its common stock for $25 per share. The company is also granting underwriters a 30-day option to acquire an additional 600,000 shares ...
Arcutis Biotherapeutics, Inc. Achieved net revenues of $2.8 million for ZORYVE® (roflumilast) cream 0.3% in the first quarter of 2023, with unit demand growth nearly doubling quarter-over-quarter ...The replay of the webcast will be available on the Arcutis website following the call. About Arcutis Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions.Nov 03, 2023. Report of unscheduled material events or corporate event. 8-K. 0001787306-23-000122.pdf. 0001787306-23-000122.rtf. 0001787306-23-000122.xls. EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View HTML. Nov 03, 2023. Quarterly report which provides a continuing view of a company's financial position.The replay of the webcast will be available on the Arcutis website following the call. About Arcutis Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions.Shares of Arcutis Biotherapeutics ... The healthcare company's stock closed last week at $8.96 a share and fell to as low as $7.47 on Thursday after Arcutis reported trial data regarding a ...What this means: InvestorsObserver gives Arcutis Biotherapeutics Inc (ARQT) an overall rank of 33, which is below average. Arcutis Biotherapeutics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 33 means that 67% of stocks appear more favorable to our system.Nov 27, 2023 · The stock of Arcutis Biotherapeutics Inc (ARQT) has seen a -2.21% decrease in the past week, with a -15.82% drop in the past month, and a -75.12% decrease in the past quarter. The volatility ratio for the week is 13.81%, and the volatility levels for the past 30 days are at 11.73% for ARQT. The […] Arcutis Biotherapeutics, Inc. (ARQT) Stock Price | Stock Quote Nasdaq - MarketScreener ARCUTIS BIOTHERAPEUTICS, INC. Equities ARQT US03969K1088 Biotechnology & …
ARQT Stock Chart & Stats Advanced Chart > -74.69% Day’s Range $0 - $0 52-Week Range $1.77 - $18.19 Previous Close $2.03 Volume 1.23M Average Volume (3M) 2.25M …Since the trade, Arcutis Biotherapeutics Inc's stock has declined by 20.89%, and it has plummeted by 91.54% since its IPO. The year-to-date performance is also down by 86.8%. With no applicable GF ...In addition, Arcutis has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the public offering price, less underwriting discounts and ...Instagram:https://instagram. how much is a quarter worth from 1776ftabxt rowe price new era fundclear secure stock August 8, 2023 at 4:02 PM · 11 min read. Arcutis Biotherapeutics, Inc. Achieved total revenues of $5.2 million in the second quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream ...Stock analysis for Arcutis Biotherapeutics Inc (ARQT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. dividend schdvodacom south africa These 8 analysts have an average price target of $25.62 versus the current price of Arcutis Biotherapeutics at $2.49, implying upside. Below is a summary of how these 8 analysts rated Arcutis ...20 thg 10, 2023 ... Arcutis is selling 32,500,000 shares of common stock and, in lieu of common stock ... Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is an early ... semiconductor stocks etf View All The Investor Relations website contains information about Arcutis Biotherapeutics's business for stockholders, potential investors, and financial analysts.Get the latest Arcutis Biotherapeutics, Inc. (ARQT) stock news and headlines to help you in your trading and investing decisions. ... Nov. 29, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc ...Dec 1, 2023 · See the latest Arcutis Biotherapeutics Inc Ordinary Shares stock price (ARQT:XNAS), related news, valuation, dividends and more to help you make your investing decisions.